SCHEMBL6292297

SCHEMBL6292297

CCCC1=C(C#N)C(c2cccc(C)n2)c2c[nH]nc2N1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.38
KDM4E B2RXH2 6/20 0.38
NR3C2 P08235 1/20 0.35
HSD17B10 Q99714 5/20 0.33
GAA P10253 3/20 0.33
HPGD P15428 3/20 0.33
CASP1 P29466 3/20 0.33
CASP7 P55210 3/20 0.33
GLA P06280 1/20 0.33
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MET P08581 1/20 0.31
USP2 O75604 1/20 0.31
TP53 P04637 1/20 0.31
ALOX15 P16050 1/20 0.31
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6296757 0.81 ALDH1A1 (0.43) ALDH1A1KDM4ENR3C2HSD17B10GAA
SCHEMBL6292239 0.81 NR3C2 (0.40) ALDH1A1KDM4ENR3C2HSD17B10GAA
SCHEMBL6297368 0.79 HSD17B10 (0.36) ALDH1A1KDM4ENR3C2HSD17B10MAPT
SCHEMBL6296586 0.79 ALDH1A1 (0.35) ALDH1A1KDM4ENR3C2HSD17B10GAA
SCHEMBL6297233 0.79 ALDH1A1 (0.36) ALDH1A1KDM4ENR3C2HSD17B10HPGD
SCHEMBL6292466 0.78 ALDH1A1 (0.40) ALDH1A1KDM4ENR3C2HSD17B10GAA
SCHEMBL6297275 0.78 CDK1 (0.40) ALDH1A1KDM4ENR3C2HSD17B10GAA
SCHEMBL6293553 0.78 HSD17B10 (0.32) ALDH1A1KDM4ENR3C2HSD17B10MAPT
SCHEMBL6296675 0.78 NR3C2 (0.33) ALDH1A1KDM4ENR3C2HSD17B10MAPT
SCHEMBL6760910 0.78 NR3C2 (0.33) ALDH1A1KDM4ENR3C2HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A9 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2002-10-10 WO disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB ALDH1A1 944/4885KDM4E 1992/4885NR3C2 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.